drugset / Trial / NCT04858256
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Phase 2
Recruiting
100 enrolled
University of Michigan Rogel Cancer Center
CTI BioPharma · collabHoosier Cancer Research Network · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Timeline
- Start
- 2023-03-29
- Primary completion
- 2027-11
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pacritinib | Small molecule | 200 mg | Oral |